A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

NICE’s healthtech guidance provided me with the perfect catalyst for change.

Evidence-based recommendations for the health and social care sector, developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

To have a good experience of NHS services people must be treated with empathy, dignity and respect. This is also fundamental for developing good relationships between people providing services and ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

There is a simple discount patient access scheme for mepolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UK.pas@gsk.com ...

Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...